Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Oncologic Sutent Will Have Dosing, Slight Price Advantage Over Nexavar

Executive Summary

Pfizer's newly approved oncologic Sutent will have a dosing advantage and will be priced at a slight discount compared to Bayer/Onyx' Nexavar

You may also be interested in...



Torisel’s Positive Effect on Overall Survival Expected To Drive Sales

Wyeth is projecting that Torisel will capture a 25 percent share of the global renal cell carcinoma market within three years following its July launch

Torisel’s Positive Effect on Overall Survival Expected To Drive Sales

Wyeth is projecting that Torisel will capture a 25 percent share of the global renal cell carcinoma market within three years following its July launch

NME Slump Continues: FDA Clears 18 Novel Drugs In 2006, Same As 2005

FDA's final approval tally of new molecular entities in 2006 is almost a 25-year low, despite early signs that the agency was on pace to best last year's final count of NME approvals

Related Content

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel